Cross-source evidence timeline
Maridebart cafraglutide research timeline
Follow 14 selected, directly cited source records from December 3, 2025 through August 13, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.
Source year
2026
Literature metadata
Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications.↗
PubMed lists PMID 42592044 in Antibody therapeutics as Journal Article, Review, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug maridebart-cafraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: June 1, 2026 · day precisionAdded to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT07313761↗
PeptideScanner retained ClinicalTrials.gov record NCT07313761 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗
Added to PeptideScanner August 14, 2026Clinical trials
ClinicalTrials.gov record NCT07684235↗
PeptideScanner retained ClinicalTrials.gov record NCT07684235 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗
Added to PeptideScanner August 14, 2026Clinical trials
ClinicalTrials.gov record NCT07037433↗
PeptideScanner retained ClinicalTrials.gov record NCT07037433 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗
Added to PeptideScanner August 13, 2026Clinical trials
MariTide bioavailability study record updated↗
ClinicalTrials.gov lists a completed Maridebart cafraglutide study sponsored by Amgen.↗
Added to PeptideScanner July 22, 2026Clinical trials
ClinicalTrials.gov record NCT07037459↗
PeptideScanner retained ClinicalTrials.gov record NCT07037459 at 2026-08-10T18:10:04.222Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗
Added to PeptideScanner August 13, 2026Clinical trials
ClinicalTrials.gov record NCT07441252↗
PeptideScanner retained ClinicalTrials.gov record NCT07441252 at 2026-07-30T16:19:03.063Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗
Added to PeptideScanner August 8, 2026Clinical trials
ClinicalTrials.gov record NCT07226765↗
PeptideScanner retained ClinicalTrials.gov record NCT07226765 at 2026-07-30T16:19:03.046Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT07225686↗
PeptideScanner retained ClinicalTrials.gov record NCT07225686 at 2026-07-30T16:19:03.064Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗
Added to PeptideScanner August 8, 2026Literature metadata
PubMed record PMID 41337722↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41337722 at 2026-07-30T16:23:39.188Z. PubMed recorded a metadata revision date of 2026-03-04 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 10, 2026Literature metadata
PubMed record PMID 41337723↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41337723 at 2026-07-30T16:23:39.188Z. PubMed recorded a metadata revision date of 2026-03-04 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 10, 2026Clinical trials
ClinicalTrials.gov record NCT07229157↗
PeptideScanner retained ClinicalTrials.gov record NCT07229157 at 2026-07-30T16:25:18.016Z. Its registry update date was 2026-01-23, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗
Added to PeptideScanner August 9, 2026
Source year
2025
Clinical trials
ClinicalTrials.gov record NCT06987695↗
PeptideScanner retained ClinicalTrials.gov record NCT06987695 at 2026-07-30T18:18:33.507Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.↗
Added to PeptideScanner August 9, 2026Literature metadata
PubMed record PMID 41337724↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41337724 at 2026-07-30T18:19:18.413Z. PubMed recorded a metadata revision date of 2025-12-03 and an Entrez history date of 2025-12-03. PeptideScanner associated this retained record with the identity slug maridebart-cafraglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 10, 2026